A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device

NCT01484197 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: 75 µg indacaterol maleate (LB)
DRUG: 75 µg indacaterol maleate (PoS)
DRUG: 37.5 µg indacaterol maleate (PoS)
DRUG: placebo to indacaterol (LB)
DRUG: placebo to indacaterol (PoS)

Sponsor

Novartis Pharmaceuticals